Pharmaceutical

Bionomics to advance non-SSRI PTSD candidate to Phase III

Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.

Mar 22, 2024 - 00:00
Bionomics to advance non-SSRI PTSD candidate to Phase III
Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.
Read the original article

Tags:

Previous Article

Molecular glues are the latest craze in pharma research, but what are they?

Next Article

Capstan secures $175m Series B funds for CAR-T therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Raleigh-Durham challenges Boston as biomanufacturing hub of the future

STAT+: Raleigh-Durham challenges Boston as biomanufactu...

Feb 1, 2024

STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation

STAT+: Venture capital is still pouring into drug resea...

Dec 23, 2023

MSD sets sights on bispecific antibody market with Curon acqusition

MSD sets sights on bispecific antibody market with Curo...

Aug 11, 2024